PortfoliosLab logo
ASM vs. SRPT
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between ASM and SRPT is -0.80. This indicates that the assets' prices tend to move in opposite directions. Negative correlation can be particularly beneficial for diversification and risk management, as one asset may offset the losses of the other during market fluctuations.


Performance

ASM vs. SRPT - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Avino Silver & Gold Mines Ltd. (ASM) and Sarepta Therapeutics, Inc. (SRPT). The values are adjusted to include any dividend payments, if applicable.

Loading data...

Key characteristics

Daily Std Dev

ASM:

61.49%

SRPT:

216.95%

Max Drawdown

ASM:

-2.02%

SRPT:

-43.03%

Current Drawdown

ASM:

0.00%

SRPT:

-43.03%

Fundamentals

Market Cap

ASM:

$366.34M

SRPT:

$3.56B

EPS

ASM:

$0.06

SRPT:

-$2.64

PEG Ratio

ASM:

0.00

SRPT:

159.25

PS Ratio

ASM:

5.54

SRPT:

1.60

PB Ratio

ASM:

2.91

SRPT:

3.12

Total Revenue (TTM)

ASM:

$53.79M

SRPT:

$2.23B

Gross Profit (TTM)

ASM:

$20.86M

SRPT:

$1.82B

EBITDA (TTM)

ASM:

$16.66M

SRPT:

$251.31M

Returns By Period


ASM

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

SRPT

YTD

N/A

1M

N/A

6M

N/A

1Y

N/A

5Y*

N/A

10Y*

N/A

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

ASM vs. SRPT — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ASM
The Risk-Adjusted Performance Rank of ASM is 9797
Overall Rank
The Sharpe Ratio Rank of ASM is 9898
Sharpe Ratio Rank
The Sortino Ratio Rank of ASM is 9797
Sortino Ratio Rank
The Omega Ratio Rank of ASM is 9393
Omega Ratio Rank
The Calmar Ratio Rank of ASM is 9797
Calmar Ratio Rank
The Martin Ratio Rank of ASM is 9797
Martin Ratio Rank

SRPT
The Risk-Adjusted Performance Rank of SRPT is 22
Overall Rank
The Sharpe Ratio Rank of SRPT is 44
Sharpe Ratio Rank
The Sortino Ratio Rank of SRPT is 33
Sortino Ratio Rank
The Omega Ratio Rank of SRPT is 22
Omega Ratio Rank
The Calmar Ratio Rank of SRPT is 22
Calmar Ratio Rank
The Martin Ratio Rank of SRPT is 00
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

ASM vs. SRPT - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for Avino Silver & Gold Mines Ltd. (ASM) and Sarepta Therapeutics, Inc. (SRPT). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.



Loading data...

Dividends

ASM vs. SRPT - Dividend Comparison

Neither ASM nor SRPT has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

ASM vs. SRPT - Drawdown Comparison

The maximum ASM drawdown since its inception was -2.02%, smaller than the maximum SRPT drawdown of -43.03%. Use the drawdown chart below to compare losses from any high point for ASM and SRPT. For additional features, visit the drawdowns tool.


Loading data...

Volatility

ASM vs. SRPT - Volatility Comparison


Loading data...

Financials

ASM vs. SRPT - Financials Comparison

This section allows you to compare key financial metrics between Avino Silver & Gold Mines Ltd. and Sarepta Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.00200.00M400.00M600.00M800.00M20212022202320242025
24.38M
744.86M
(ASM) Total Revenue
(SRPT) Total Revenue
Values in USD except per share items

ASM vs. SRPT - Profitability Comparison

The chart below illustrates the profitability comparison between Avino Silver & Gold Mines Ltd. and Sarepta Therapeutics, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

-100.0%-50.0%0.0%50.0%100.0%20212022202320242025
42.9%
81.5%
(ASM) Gross Margin
(SRPT) Gross Margin
ASM - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Avino Silver & Gold Mines Ltd. reported a gross profit of 10.46M and revenue of 24.38M. Therefore, the gross margin over that period was 42.9%.

SRPT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a gross profit of 607.29M and revenue of 744.86M. Therefore, the gross margin over that period was 81.5%.

ASM - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Avino Silver & Gold Mines Ltd. reported an operating income of 8.27M and revenue of 24.38M, resulting in an operating margin of 33.9%.

SRPT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported an operating income of -300.39M and revenue of 744.86M, resulting in an operating margin of -40.3%.

ASM - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Avino Silver & Gold Mines Ltd. reported a net income of 5.09M and revenue of 24.38M, resulting in a net margin of 20.9%.

SRPT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Sarepta Therapeutics, Inc. reported a net income of -447.51M and revenue of 744.86M, resulting in a net margin of -60.1%.